Michael Cola . Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts) Three Months … General Counsel. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support See the full leadership team at Craft. Joe Hand 1-877-742-8466 info@phathompharma.com. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Prior to Celgene, he was a litigation attorney at the international law firm of Jones Day. Chief Operating Officer. 25, 2020– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief … Phathom Pharmaceuticals's Chairman is Tadataka Yamada. James Topper. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Distributed by Public, unedited and unaltered, on 08 September 2020 12:29:03 UTC Eckhard Leifke is Chief Medical Officer at Phathom Pharmaceuticals. Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com. Phathom Pharmaceuticals Provides Clinical Trial Status Update ... Joe Hand 1-877-742-8466 info@phathompharma.com. Thank you for accessing our content on the Topio Networks Market Intelligence Center. Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. Joe Hand. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer. Investors: Patti Bank Westwicke Partners 415-513-1284 patti.bank@westwicke.com Chief Medical Officer. Phathom Pharmaceuticals, Inc. (PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has randomized the first new patients in each of its two Phase 3 clinical trials since temporarily pausing new patient randomization in response to the COVID-19 pandemic. 90 companies . Todd Branning. Media Contacts: Joe Hand 1-877-742-8466 info@phathompharma.com. Executive Vice President, Global Human Resources & Corporate Services, Senior Vice President, Global Human Resources and Corporate Services, Intelligent Assistance and Bots Ecosystem. Last updated: 02/05/2021. To access all the content for free, please sign up by entering your email. Nick Benedetto 1-877-742-8466 media@phathompharma.com. Thank you for your continued support. Dr. Leifke is the former Chief Medical Officer at Omeros. Phathom Pharmaceuticals to Present at 40 th Annual Cowen and Company Health Care Conference on March 2, 2020 FLORHAM PARK, NJ.–Feb. Phathom Pharmaceuticals Inc. published this content on 08 September 2020 and is solely responsible for the information contained therein. PHATHOM PHARMACEUTICALS, INC. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Terrie Curran Recommended Market Profiles. Investor Contact: Patti Bank Westwicke Partners 415-513-1284 patti.bank@westwicke.com. Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020 Email Print Friendly Share February 25, 2020 16:35 ET | Source: Phathom Pharmaceuticals Joe Hand 1-877-742-8466 info@phathompharma.com. Larry Miller. Same platform but with new and improved features. FLORHAM PARK, N.J., Feb. 25, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing. Joe Hand 1-877-742-8466 info@phathompharma.com. In the Pharmaceuticals industry, Joe Hand has 19,196 colleagues in 2,035 companies located in 74 countries. FLORHAM PARK, N.J., July 13, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing. FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company … Director. Dec-2019. FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that company management will participate in one-on-one meetings at the upcoming 19th Annual Needham Virtual … Dans le secteur Pharmacie, Joe Hand a 18 914 collègues dans 2 012 entreprises basées dans 74 pays. Phathom Pharmaceuticals Inc. published this content on 08 September 2020 and is solely responsible for the information contained therein. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P- CAB). Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a … Joe Hand 1-877-742-8466 info@phathompharma.com. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Joe Hand. Tadataka Yamada. Investor Contact: Patti Bank Westwicke Partners Phathom Pharmaceuticals's Chairman is Tadataka Yamada. Mr. Hand holds a BBA from the University of Notre Dame and a JD from New York University School of Law. Investor Contact: Patti Bank Westwicke Partners Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Chief Medical Officer. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. David Socks. Phathom Pharmaceuticals serves gastrointestinal and pharmaceutical industries in the State of Illinois. Chief Administrative Officer. Azmi Nabulsi. In the Pharmaceuticals industry, Joe Hand has 19,196 colleagues in 2,035 companies located in 74 countries. The Company focuses on development and commercialization for gastrointestinal (GI) diseases and disorder treatments. About Phathom Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Dec-2019. Phathom Pharmaceuticals (“Phathom”) is committed to protecting your privacy. Eckhard Leifke. 25, 2020– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief … Chief Administrative Officer. At Phathom Pharmaceuticals, Joe Hand has 6 colleagues who can be contacted including Terrie Curran (CEO & Director), Mark Stenhouse (Director)… Industry Colleagues. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. About Phathom Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Chief Financial Officer. Phathom Pharmaceuticals is committed to protecting your privacy. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). FLORHAM PARK, N.J., May 28, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing. Chief Administrative Officer, Phathom Pharmaceuticals Inc, Exec VP:Global Human Resources, Celgene Corp. Phathom Pharmaceuticals, Inc. operates as a biopharmaceutical company. Chairman. Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Monday, 28 October 2019 benzinga. www.vbprofiles.com is now www.topionetworks.com. … PHATHOM PHARMACEUTICALS, INC. (+1) 877-742-8466 info@phathompharma.com. Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Martin J. Gilligan as Chief Commercial Officer.Mr. Joe Hand. View All. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com. Suite 800 Media Contact: ... Patti Bank Westwicke Partners 415-513-1284 patti.bank@westwicke.com. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities – Cardiovascular and Metabolism and Global Head/Vice President of Late Stage Development – Diabetes. 51 Biggest Movers From Friday Filter news. Investor Contact: Patti Bank Westwicke Partners Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. Dr. Leifke is the former Chief Medical Officer at Omeros. Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatmen Dec-2019. Joe Hand 1-877-742-8466 info@phathompharma.com. Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from … Joe Hand 1-877-742-8466 [email protected] Media Contact: Nick Benedetto 1-877-742-8466 [email protected] Investor Contact: Patti Bank Westwicke Partners 415-513-1284 ... PHATHOM PHARMACEUTICALS, INC. PHATHOM PHARMACEUTICALS, INC. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. FLORHAM PARK, N.J., April 09, 2020 -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing. He was also responsible for the management of Celgene’s global facilities footprint. Dec-2019. IPO Companies (2019) 10,000 or More employees. Colleagues at Phathom Pharmaceuticals. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities – Cardiovascular and Metabolism and Global Head/Vice President of Late Stage Development – Diabetes. Eckhard Leifke. In that capacity, he was responsible for all employee-related activities including talent development, recruiting, and compensation and benefits. Distributed by Public, unedited and unaltered, on 08 September 2020 12:29:03 UTC Larry Miller. We look forward to providing you with even more cutting-edge market research, as Topio Networks. 8,760 executive movements have been recorded in the last 12 months. At Phathom Pharmaceuticals, Joe Hand has 6 colleagues who can be contacted including Terrie Curran (CEO & Director), Mark Stenhouse (Director)… Industry Colleagues. Chief Financial Officer. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. The company offers Vonoprazan, a small molecule potassium-competitive acid blocker to treat gastroesophageal reflux disease, including erosive esophagitis, gastric and duodenal ulcer, and low dose aspirin-associated ulcer. Media: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 mikebeyer@sambrown.com. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. Colleagues at Phathom Pharmaceuticals. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Joe Hand 1-877-742-8466 info@phathompharma.com. Chief Administrative Officer. Eckhard Leifke is Chief Medical Officer at Phathom Pharmaceuticals. David Socks. Dec-2019. Chez Phathom Pharmaceuticals, Joe Hand a 6 collègues qui peuvent être contactés dont Terrie Curran (CEO & Director), Mark Stenhouse (Director)… Collègues dans l'industrie. Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com. 8,760 executive movements have been recorded in the last 12 months. Phathom Pharmaceuticals's key executives include Tadataka Yamada and 15 others. Other executives include Terrie Curran, President, Chief Executive Officer & Director; Azmi Nabulsi, Chief Operating Officer and 13 others. 2150 East Lake Cook Road Dec-2019. About | Events | Newsletters | FAQ | Work with … General Counsel. Chief Financial Officer. View All. Source: Phathom Pharmaceuticals, Inc. Joe Hand 1-877-742-8466 info@phathompharma.com. Mr. Hand is the former Executive Vice President, Global Human Resources and Corporate Services at Celgene as well as a former member of its Executive Committee. Joe Hand is Chief Administrative Officer at Phathom Pharmaceuticals Inc. See Joe Hand's compensation, career history, education, & memberships. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com. We believe we can change the status quo of treatment for acid-related disorders. President, Chief Executive Officer & Director. Curated profile of Joe Hand, Chief Administrative Officer, Phathom Pharmaceuticals including career history, news and intelligence, portfolio companies and investments. Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com. Phathom … New Jersey Corporate Headquarters 100 Campus Drive, Suite 102 Florham Park, NJ 07932 IPO Companies (2019) 10,000 or More employees. About Phathom Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Terrie Curran. Phathom Pharmaceuticals to Present at 40 th Annual Cowen and Company Health Care Conference on March 2, 2020 FLORHAM PARK, NJ.–Feb.